AstraZeneca PLC
AZN Real Time Price USDRecent trades of AZN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AZN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,240,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$640,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Insurance
-
$650,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$700,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$80,000 Feb 07, 2024 Issue: Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations
-
$830,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
Estimated quarterly lobbying spending
AZN Revenue by Segment or Geography
New patents grants
-
Patent Title: Maleate salts of a quinazoline derivative useful as an antiangiogenic agent Oct. 14, 2014
-
Patent Title: Pyrrolo[3,2-d]pyrimidin-4-one derivatives and their use in therapy Oct. 14, 2014
-
Patent Title: Inhibitors of protein kinases Sep. 23, 2014
-
Patent Title: Pyrazolylaminopyridine derivatives useful as kinase inhibitors Sep. 16, 2014
-
Patent Title: Process for preparing dipeptidyl peptidase iv inhibitors and intermediates therefor Aug. 19, 2014
-
Patent Title: Crystal forms of saxagliptin and processes for preparing same Aug. 12, 2014
-
Patent Title: Inhaler 624 Aug. 12, 2014
-
Patent Title: Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same Jul. 29, 2014
-
Patent Title: Pyrimidline derivatives having immune modulating properties that act via tlr7 for the treatment of viral or allergic diseases and cancers Jul. 01, 2014
-
Patent Title: Process for the manufacture of 4-fluoro-2-methyl-1h-indol-5-ol Jun. 17, 2014
-
Patent Title: Crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide Jun. 10, 2014
-
Patent Title: Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors Jun. 03, 2014
-
Patent Title: Benzamide compounds useful as histone deacetylase inhibitors May. 27, 2014
-
Patent Title: Compound May. 27, 2014
-
Patent Title: Quinazoline derivatives as tyrosine kinase inhibitors May. 27, 2014
-
Patent Title: Pyrimidine sulphonamide derivatives as chemokine receptor modulators May. 13, 2014
-
Patent Title: Biphenyloxyacetic acid derivatives for the treatment of respiratory disease May. 13, 2014
-
Patent Title: Heterocyclic compounds as ccr2b antagonists Apr. 29, 2014
-
Patent Title: Compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation Apr. 15, 2014
-
Patent Title: Therapeutic agents Apr. 01, 2014
-
Patent Title: Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor Mar. 25, 2014
-
Patent Title: Chemical compounds Mar. 18, 2014
-
Patent Title: Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9h-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy Mar. 18, 2014
-
Patent Title: Chromenone derivatives Mar. 18, 2014
-
Patent Title: Dental implant Mar. 11, 2014
-
Patent Title: Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt Feb. 25, 2014
-
Patent Title: Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections Feb. 25, 2014
-
Patent Title: Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits Feb. 18, 2014
-
Patent Title: Dibenzothiazepine derivatives and uses thereof—424 Feb. 18, 2014
-
Patent Title: Quinazoline derivatives as vegf inhibitors Feb. 04, 2014
-
Patent Title: Compounds Jan. 14, 2014
-
Patent Title: Inhalation device and a method for assembling said inhalation device Dec. 31, 2013
-
Patent Title: N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof Dec. 10, 2013
-
Patent Title: Inhalation device Nov. 19, 2013
-
Patent Title: Entraining powder in an airflow Nov. 12, 2013
-
Patent Title: 9-substituted 8-oxoadenine compound Nov. 05, 2013
-
Patent Title: Composition for inhalation Nov. 05, 2013
-
Patent Title: Heterocyclic urea derivatives and methods of use thereof Oct. 29, 2013
-
Patent Title: Pyridine compounds Oct. 29, 2013
-
Patent Title: Process for preparing [1 Oct. 22, 2013
-
Patent Title: Chemical compounds Oct. 08, 2013
-
Patent Title: (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds Oct. 01, 2013
-
Patent Title: Chromenone derivatives Sep. 10, 2013
-
Patent Title: Inhaler device that reduces the risk for miscounting a dosage Sep. 10, 2013
-
Patent Title: Phenoxyacetic acid derivatives useful for treating respiratory diseases Sep. 03, 2013
-
Patent Title: Bi-aryl amide compounds as crth2 receptor modulators Aug. 13, 2013
-
Patent Title: 2-pyridone derivatives as neutrophil elastase inhibitors and their use Aug. 06, 2013
-
Patent Title: Quinazoline derivatives as angiogenesis inhibitors Jul. 23, 2013
-
Patent Title: Elastic surgical ring clip/loader and a method Jul. 23, 2013
-
Patent Title: 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer Jul. 16, 2013
Federal grants, loans, and purchases
- $1,810 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $2,076 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $0 2024-04-24 00:00:00 Agency: Department of Veterans Affairs
- $2,023 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $1,764 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $20,322 2023-07-27 00:00:00 Agency: Department of Health and Human Services
Estimated quarterly amount awarded from public contracts
Recent insights relating to AZN
Recent picks made for AZN stock on CNBC
ETFs with the largest estimated holdings in AZN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AZN stock a Buy, Sell, or Hold?
- What is the price target for $AZN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AZN stock?
- Who owns the most shares of $AZN stock?
- What funds own $AZN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AZN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.